Blog Read the latest perspectives from our team of subject matter experts and others AI in Clinical TrialsAt Fierce JPM Week 2026, Ariel Katz, CEO and Co-founder of H1, sat down with Paul Bridges, PhD, President of Parexel’s Consulting organization, for a fireside chat that cut… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact KOL Engagement Patient Representation Provider Data Post Industries:Digital Health Health Plans Pharmaceutical & Biotechnology KOL EngagementNurses: The Unsung Heroes in Pharma and BiotechHealthcare providers are often the first line of defense in ensuring that people receive the medical treatment they need. But nurses are often overlooked as a solution to addressing patient… Continue reading → Read the articleno KOL EngagementPatient RepresentationFour Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in MedicinePharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education. With the rise… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationData Networks & Guiding Clinical Trials – Six Metrics for Powering Trials to Reach Vulnerable Patient PopulationsFor clinical operations and development clinical feasibility teams, and patient representation leaders, as well as health economics and outcomes research (HEOR) teams, it is essential to understand the considerations when… Continue reading → Read the articleno KOL EngagementThree Ways Field Medical Teams Can Close Care Gaps and Increase Scientific Share of VoiceAs the primary interface between healthcare providers (HCPs) and pharmaceutical companies, medical science liaisons (MSLs) have a unique opportunity to engage with HCPs in clinical discussions and bridge care gaps… Continue reading → Read the articleno Drug DevelopmentPatient Representation3 Common Questions Related to Clinical Trial Performance DataOver the past decade, the cost and time impact to bring drugs to market have been increasing. With the recent trends in healthcare (more inclusion for both patients as well… Continue reading → Read the articleno CommercializationUnlocking Value-Based Care: How Pharma & MedTech Companies Can Thrive in a New Age of Private Payers and Population HealthAs the healthcare industry shifts to value-based care, private payers and population health are taking the lead in determining patient care. For pharma and med tech companies, this shift… Continue reading → Read the articleno«‹567891011›»
